Research published in the journal, Science, and financially supported by the Wellcome Trust, describes how a new class of antibiotics could be developed to treat multi-drug resistant Staphylococcus aureus (MRSA).
ReNeuron Group Plc has asked for clearance from the UK regulator to test its stem-cell therapy for stroke in man for the first time, having failed thus far to get permission for a human study from the US Food and Drug Administration.
Antisoma Plc has ended its financial year with a profit and reported progress across all of its drug development programmes which focus on major indications in the field of oncology.
BTG Plc has announced an all-share offer for Protherics Plc valued at £218.1 million, ending weeks of speculation about the fate of Protherics, a specialty pharmaceutical company.
The UK’s Human Fertilisation and Embryology Authority, which regulates in vitro fertilisation treatment and embryo research, has appointed six new members.
Takeda Pharmaceutical Company Ltd has decided to start a Phase 3 study in Japan of a new gastrointestinal lipase inhibitor for obesity, cetilistat, which will trigger a $3 million payment to the compound’s developer, Alizyme Plc.
The Scottish specialty pharmaceutical company, ProStrakan Group Plc, has received approval from the US Food and Drug Administration for a transdermal patch which can be used to prevent nausea and vomiting associated with the administration of chemotherapy.
A privately-owned US drug discovery company with operations in Cambridge, UK and Heidelberg, Germany has entered into a strategic alliance with GlaxoSmithKline to discover and develop kinase-targeted therapeutics to treat inflammatory diseases.
A new biopharmaceutical company has been created in Switzerland to focus on the development of anti-infectives for women’s health. The company, Lumavita AG, is based in Basle, and is being supported by Atlas Venture, BB Biotech Ventures and BioMedInvest. On 2 September 2008, it announced the successful closing of a Series A financing for €11 million.
Pfizer Inc. has withdrawn its licensing applications in the US and Europe for the skin treatment, dalbavancin, in order to conduct a second Phase 3 trial. The withdrawals were announced on 9 September 2008.